Bio Updates StocksDiva Eli Lilly and Company (NYSE:

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone wowhappens28 #4624
Bio Updates StocksDiva


Eli Lilly and Company (NYSE: LLY) announced it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy. The decision was not based on safety concerns. The tabalumab Phase 3 program for systemic lupus erythematosus, ILLUMINATE, is ongoing and will continue as planned.

In December 2012, Lilly discontinued the Phase 3 RA registration study FLEX-M for lack of treatment effect. FLEX-M was investigating tabalumab in patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy.

Based on FLEX-M findings, an interim futility analysis was conducted of the FLEX-V study, which was investigating tabalumab for the treatment of patients with moderate-to-severe RA who had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors.

Based on the outcomes of these two separate interim futility analyses, Lilly has decided to discontinue development of tabalumab in the current RA program. All ongoing Phase 2 and Phase 3 RA studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "Autoimmune disorders are highly individualized. We believe that targeting BAFF with a molecule such as tabalumab may still represent an important advance for patients, and therefore we will continue the ongoing Phase 3 tabalumab lupus program."

The decision to stop the current RA program for tabalumab is expected to result in a first-quarter charge to research and development expense of approximately $50 million. The company's previously issued financial guidance for 2013 remains unchanged.


Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data , Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923 (dextromethorphan hydrobromide and quinidine sulfate). The company has requested a meeting with the FDA to discuss the full development path for AVP-786.

"The results of this study are very encouraging," said Joao Siffert, MD, chief scientific officer for Avanir. "We were able to successfully replicate the steady-state plasma levels of AVP-923, but with a substantially lower dose of quinidine. Given these results, we believe that AVP-786 would be an ideal candidate to test in one or more of our ongoing clinical programs."

Avanir also announced today that the company intends to modify the enrollment target of its ongoing phase II clinical study of AVP-923 in central neuropathic pain in multiple sclerosis to 200 patients.

"With the encouraging pharmacokinetic results in hand, we have made the decision to accelerate the completion of the PRIME study, as we believe AVP-786 has the potential to be a preferable development compound," said Joao Siffert, MD. "We plan to use the data from the PRIME study to guide the further development of AVP-786."

As a result of this change, the company now expects to have data from the PRIME study in the fourth calendar quarter of 2013.

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced it will present at the 15th Annual BIO CEO & Investor Conference on February 11th at 9:30am EST in the Basildon room at the Waldorf=Astoria in New York City.

Allergan, Inc. (NYSE: AGN) (“Allergan”) and MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (“MAP”) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to the tender offer for all of the outstanding shares of common stock of MAP by Groundhog Acquisition, Inc. (“Purchaser”), a wholly-owned subsidiary of Allergan.

Amgen (NASDAQ: AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City.

Anthera Pharmaceuticals, Inc.(Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 2013 Leerink Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at approximately 8:00 am Eastern Time.

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann Global Healthcare Conference on Thursday, February 14, 2013 at 1:30 p.m.

CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2013 BIO CEO & Investor Conference on Monday, February 11, 2013 at 11:00 a.m.

China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced the completion of the previously announced transaction with Cordlife Services (S) Pte. Ltd., a subsidiary of the Company's strategic affiliate, Cordlife Limited (CBB.AU) ("Cordlife"), a cord blood and tissue banking services provider listed on the Australian Securities Exchange.

CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt of notice on February 1, 2013 from the NYSE MKT LLC (the “NYSE MKT”) that the NYSE MKT granted it an extension until April 15, 2013 to regain compliance with the continued listing standards of the NYSE MKT.

Digirad Corporation (NASDAQ: DRAD) announced today R. King Nelson, former Chairman, and Gerhard F. Burbach have tendered their resignations from the Board of Directors after more than a decade of service to the Board and management team at Digirad.

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced results from its randomized ReCharge Pivotal Trial of VBLOC® vagal blocking therapy for the treatment of obesity.

ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, has appointed Mohan Gopalkrishnan as Vice President - Operations.

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2012 financial results on Thursday, February 21, at 9:00 a.m. Eastern Time.

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and twelve months ended December 31, 2012, following the close of the market on Tuesday, February 19, 2013.

Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with patented proprietary medical technology for the growing $55 Billion US home healthcare industry, is pleased to announce that Charles Vorwaller, a consultant with Ingen, has introduced Thomas Childers to the company and has agreed to help create sales of the Smart Nasal Cannula and Oxyview oxygen flow meter to his government clientele.

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2012 on February 27, 2013 after the close of the financial markets.

KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share.

LiveWire Ergogenics, Inc. (OTCQB: LVVV) has provided a corporate update of the company's activities and accomplishments in 2012 during which LiveWire completed the transition from a private company to a fully reporting public company with audited financials.

MeadWestvaco Corporation (NYSE: MWV), a global leader in packaging and packaging solutions, announced today the expansion of its pharmaceutical manufacturing Centre of Excellence, based in Hemer, Germany.

MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter ended December 31, 2012, will be released before the opening of the market on Thursday, March 7, 2013.

Novadaq® Technologies Inc. (TSX:NDQ) (NASDAQ:NVDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical procedures, today announced financial results for its fourth quarter and full year ended December 31, 2012.

Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin associated serine protease-2 (MASP-2) program.

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that it will report financial results for the fourth quarter and full year 2012 ended December 31, 2012 after market closes on Thursday, February 21, 2013.

Opexa Therapeutics, Inc. (NASDAQ:OPXA) a company developing Tcelna™ (imilecleucel-T), a novel T-cell therapy for multiple sclerosis (MS), today announced it has priced an offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3,250,000.

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year 2012 financial results after the NASDAQ Global Market closes on February 28.

Oramed Pharmaceuticals Inc. (OTCQB: ORMPD), a developer of oral drug delivery systems, announced today that NASDAQ has approved the company's application to list its shares of common stock on the NASDAQ Capital Market.

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.

Parametric Sound Corporation (NASDAQ: PAMT), a leading innovator of audio technology and solutions, today announced financial results for its first fiscal quarter ended December 31, 2012.

Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference.

RTI Biologics Inc. (RTI) (Nasdaq:RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the fourth quarter and full year of 2012.

SurePure, Inc. (OTCBB: SURP) a global leader in liquid photopurification, announced that Sigma Alimentos, a major Mexican food producer, would purchase at least three of its SurePure ultraviolet (UVC) photopurification systems.

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced it has signed its first European commercial development agreement with Netherlands-based EMELCA Bioscience for the initial phase of Venaxis' EU launch.

YM BioSciences Inc. (NYSE MKT: YMI) (TSX: YM), today reported operational and financial results for the second quarter of fiscal 2013, ended December 31, 2012.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 370

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 97

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 23

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 90

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading

Top 5 Most Recently Viewed Articles

Examining the Latest Trends in Beyond Meat's Short Selling

Updated Category News Views 624

Understanding Beyond Meat's Short Interest Dynamics Beyond Meat (NASDAQ: BYND) has seen an increase in its short percent of float, now at 4.44% higher than the last report. Currently, 24.77 million shares have been sold short, constituting a substantial 39.78% of the total shares available for trading. Given the current trading volume, it would take approximately 10.11...

Continue Reading
Vestis Corporation Faces Class Action Amid Financial Woes

Updated Category News Views 231

Vestis Corporation's Class Action Lawsuit Announcement Pomerantz LLP has formally announced a class action lawsuit targeting Vestis Corporation (NASDAQ: VSTS). This lawsuit stems from allegations of securities fraud and other improper business practices potentially committed by the Company and its executives. Investors who have incurred losses from their investments in...

Continue Reading
Join Ring Energy's Insightful Fireside Chat on Industry Trends

Updated Category News Views 192

Exciting Participation of Ring Energy in Upcoming Fireside Chat Ring Energy, Inc. (NYSE American: REI) has announced its upcoming participation in a noteworthy fireside chat hosted by Water Tower Research. Insights from Industry Leaders This engaging discussion is scheduled to take place at 10:00 AM Central Time, featuring Paul McKinney, the Chairman and Chief Executive...

Continue Reading
SEGG Media's Exciting Leap into NBA Advertising Strategy

Updated Category News Views 191

SEGG Media Strengthens Presence in the NBA SEGG Media Corporation has made significant strides in expanding its brand influence within the U.S. sports landscape. The company, which is the parent organization of Sports.com, has recently announced a strategic initiative to feature full-page advertisements in yearbooks for seven premier NBA teams during the upcoming season....

Continue Reading
Federal Home Loan Bank of Atlanta Reports Q3 2024 Financial Overview

Updated Category News Views 95

Financial Highlights of Federal Home Loan Bank of Atlanta The Federal Home Loan Bank of Atlanta has recently shared its preliminary financial highlights for the third quarter of 2024, showcasing important metrics and performance results. The Bank's quarterly outcomes signal core functionalities and adjustments aimed at sustaining a strong financial foundation. Key...

Continue Reading